單克隆抗體在血液疾病中的應(yīng)用

1、1會計(jì)學(xué)單克隆抗體在血液疾病中的應(yīng)用單克隆抗體在血液疾病中的應(yīng)用1. Coiffier B, et al. N Eng J Med 2002; 346:235242.2. Forstpointner R, et al. Blood 2006; 108:40034008.Aggressive NHLPS 03Stage IIVAge 60 yrsNo prior Rx68 x CHOPRANDOMISERituximabmaintenance4 x R/q6mo (for 2 years)Observation CR/PRRANDOMISE 45 x rituximab plus68 x CHO

2、PHabermann T, et al. J Clin Oncol 2006; 24:31213127.Time (years)R-CHOP inductionCHOP induction543210p = 0.81Rituximab maintenanceObservation1.00.20p = 0.0004Probability1.00.20Rituximab maintenanceObservation543210Time (years)Habermann T, et al. J Clin Oncol 2006; 24:31213127.n初步結(jié)果，

3、所有病例均無復(fù)發(fā)，時間尚短，不能定論。/ct/show/NCT00400478?order=; EUDRACT: 2005-0055187-90 MJ Keating personal communication改良的R-FC reduced F (20 mg/m2) and C (150 mg/m2)increased R (500 mg/m2 every 14 days, maintenance every 3 months)85% CR rate (40 evaluable patients)Tarhini J Clin Oncol

4、 2007;25:A2037012345678Years0.00.81.0 Pts. Died Treatment 190 150 Fludarabine 140 81 FC/FM 300 68 FCR1.00.201.00.20Proportion aliveR-FC (n =300)FC/FM (n =140)Fludarabine (n =190)012345678p 0.001MJ Keating personal communicationSimilar PFS and OS with F and chlorambu 評估47例ORR 94% CR 74% PR 20%：4例PR中2例MRD陰性 Grade IIIIV 中性粒細(xì)胞減少癥12%F. Bosch, etc. 2008ICML#377 初治CLL 70歲n=85RFCMq4w6隨訪CR，PRRq3m8R 500 mg/m2 day1, F 25 mg/m2 days13, C 200 mg/